960 x 350_41

Small and Large Molecule LC-MS

Accurately measuring and quantifying biomarkers in relevant matrices informs numerous aspects of clinical drug development. Biomarker assays can match patients to appropriate therapies and demonstrate a candidate drugs safety and efficacy, thus illuminating its potential for clinical and commercial success. Q2 Solutions offers a wide range of tailored and integrated liquid chromatography mass spectrometry services to support biomarker testing and quantitation, including LC/MS bioanalysis, LC/MS/MS analysis, hybrid LC-MS assays, small molecule LC/MS, and large molecule bioanalysis.

Our team has extensive experience developing and validating multiplex LC/MS assays of endogenous analytes (e.g., proteins, peptides, lipids) and small/large molecules and their metabolites. Q2 Solutions’ LC/MS/MS bioanalytical services are GLP and GCP compliant to support FDA, OECD, MHLW, and ICH standards.

Related Thought Leaders Insights


A Process of Method Development for Tissue Homogenization and Analysis to Eliminate Binding and Matrix Effects Using Surrogate Matrices

The analysis and distribution of pharmaceuticals in tissue is increasingly important in understanding the full action of drugs in vivo. Across molecular types from very small molecules to larger...

Small Molecule Bioanalytical and ADME Solutions

Q2 Solutions offers tailored and comprehensive small molecule bioanalytical and ADME laboratory services. We combine scientific excellence, high-quality project management, and outstanding delivery...

Choosing HRMS vs LBA for Bioanalysis

There is an increase in the complexity of drug modalities along with the need for more sensitive methods. Immunoassays, while often chosen as the first platform to utilize for assessing...